Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mirum Pharmaceuticals (MIRM) Amortization of Deferred Charges (2020 - 2025)

Historic Amortization of Deferred Charges for Mirum Pharmaceuticals (MIRM) over the last 5 years, with Q3 2025 value amounting to $443000.0.

  • Mirum Pharmaceuticals' Amortization of Deferred Charges rose 448.11% to $443000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.7 million, marking a year-over-year increase of 456.2%. This contributed to the annual value of $1.7 million for FY2024, which is 4870.19% up from last year.
  • Per Mirum Pharmaceuticals' latest filing, its Amortization of Deferred Charges stood at $443000.0 for Q3 2025, which was up 448.11% from $427000.0 recorded in Q2 2025.
  • In the past 5 years, Mirum Pharmaceuticals' Amortization of Deferred Charges ranged from a high of $443000.0 in Q3 2025 and a low of -$285000.0 during Q4 2021
  • For the 4-year period, Mirum Pharmaceuticals' Amortization of Deferred Charges averaged around $291500.0, with its median value being $409000.0 (2023).
  • In the last 5 years, Mirum Pharmaceuticals' Amortization of Deferred Charges tumbled by 45625.0% in 2021 and then soared by 3257.33% in 2024.
  • Mirum Pharmaceuticals' Amortization of Deferred Charges (Quarter) stood at -$285000.0 in 2021, then soared by 240.0% to $399000.0 in 2023, then rose by 4.26% to $416000.0 in 2024, then increased by 6.49% to $443000.0 in 2025.
  • Its Amortization of Deferred Charges stands at $443000.0 for Q3 2025, versus $427000.0 for Q2 2025 and $433000.0 for Q1 2025.